Tanya Harlow
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,577 of the $72,511 with a category attached, or 75.3%. Teva Pharmaceuticals USA, Inc. accounts for 80.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2020 at $31,250 and has fallen 97.6% since, to $743 in 2025. Among neurology clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $431.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$58K
- Amneal Pharmaceuticals LLC$12K
- EMD Serono, Inc.$226
- Acadia Pharmaceuticals Inc$201
- Neurocrine Biosciences, Inc.$183
- Abbott$151
- plus $1K from 24 others
Across 58 payments — averaging $276.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$16K
What the payments were for
- Consulting fees$6,2709%
- Speaking & faculty fees$54,57775%
- Travel & lodging$8,07811%
- Food & beverage$3,5865%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 69 | $58,030 |
| Amneal Pharmaceuticals LLC | 19 | $12,481 |
| EMD Serono, Inc. | 2 | $226 |
| Acadia Pharmaceuticals Inc | 10 | $201 |
| Neurocrine Biosciences, Inc. | 8 | $183 |
| Abbott | 8 | $151 |
| Boston Scientific | 6 | $146 |
| Amgen | 1 | $130 |
| Novartis | 1 | $100 |
| Genentech USA, Inc. | 1 | $91 |
| AbbVie(2 entities) | 6 | $86 |
| GE HealthCare | 3 | $70 |
| Eisai Inc. | 3 | $70 |
| Acorda Therapeutics, Inc | 4 | $62 |
| Sanofi | 2 | $51 |
| Genentech, Inc. | 3 | $48 |
| Averitas Pharma Inc. | 2 | $47 |
| Merz Pharmaceuticals, LLC | 2 | $41 |
| TG Therapeutics, Inc. | 2 | $38 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Adamas Pharmaceuticals, Inc. | 2 | $30 |
| Biogen | 2 | $29 |
| Saol Therapeutics Inc. | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Mirum Pharmaceuticals, Inc. | 1 | $24 |
| Revance Therapeutics, Inc. | 1 | $16 |
| MDD US Operations, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$53,896
- RYTARY$12,261
- Austedo XR$234
- UPLIZNA$130
- Luveris$125
- KESIMPTA$100
How this compares
$72,511 in reported general payments places this provider in the 95th percentile of 39 neurology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 28 | $243,583 |
| RytaryCarbidopa/Levodopa | 169 | $229,626 |
| NuplazidPimavanserin Tartrate | 12 | $94,322 |
| GocovriAmantadine Hcl | 17 | $76,124 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 684 | $40,188 |
| MysolinePrimidone | 12 | $35,706 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 314 | $14,109 |
| Rasagiline Mesylate | 68 | $12,787 |
| Rivastigmine | 81 | $9,191 |
| Carbidopa | 18 | $8,906 |
| Baclofen | 98 | $8,008 |
| Gabapentin | 248 | $6,290 |
| Propranolol Hcl ErPropranolol Hcl | 139 | $5,424 |
| Ipratropium Bromide | 92 | $3,308 |
| Mirtazapine | 240 | $3,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $58,030 | $243,58328 claims |
| Amneal Pharmaceuticals LLCRytary | $12,481 | $229,626169 claims |
| Acadia Pharmaceuticals IncNuplazid | $201 | $94,32212 claims |
| MDD US Operations, LLCGocovri | $15 | $76,12417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 39 neurology providers in North Dakota.
Other neurology in Fargo
- Susan ScarberryFargo$67K
- Sarah KendroudFargo$42K
- Scott BellistonFargo$9K
- Gary MillerFargo$2K
- Alexandra SequeiraFargo$2K
- Eugeniu MunteanFargo$1K
- Joyce Jimenez ZambranoFargo$777
- Jau-Shin LouFargo$349
- Merlin NelsonFargo$238
- Karen RasmussonFargo$211
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.